EX-99.1 2 ex99-1.htm EX-99.1 PURE Bioscience Reports Fiscal First Quarter 2026 Financial Results EL CAJON, Calif. - PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2025. Summary of Results of Operations - Fiscal First Quarter Net product sales were $707,000 and $555,000 for the fiscal first quarter ended October 31, 2025 and 2024, respectively. The increase of $152,000 was attributable to increased sales across our end-user customer base. Net loss for the fiscal first quarter ended October 31, 2025, was $464,000, compared to $689,000 for the fiscal first quarter ended October 31, 2024. Net loss, excluding share-based compensation, for the fiscal first quarter ended October 31, 2025, was $430,000, compared to $632,000 for the fiscal first quarter ended October 31, 2024. Net loss per share was ($0.00) and ($0.01) for the fiscal first quarter ended October 31, 2025 and 2024, respectively. As an update to the press release dated October 29, 2025, the Company is pleased…
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
PURE Bioscience, Inc.
PUREOTCEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On December 15, 2025, PURE Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the fiscal first quarter ended October 31, 2025 and related information. A copy of the press release is attached as Exhibit 99.1.…
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item
2.02. Results of Operations and Financial Condition.
On
December 15, 2025, PURE Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the fiscal
first quarter ended October 31, 2025 and related information. A copy of the press release is attached as Exhibit 99.1.
The
information in this Item 2.02 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities
Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Item 2.02 shall not be incorporated
by reference into any registration statement or other document filed with the Securities and Exchange Commission.